This review summarises the pharmacological and clinical characteristics of the IL-5-receptor monoclonal antibody benralizumab [FASENRA®] as add-on therapy for severe eosinophilic asthma in patients aged 12 years and over.1 Benralizumab has demonstrated efficacy in clinical trials in reducing rates of asthma exacerbation and use of maintenance oral corticosteroids in patients with severe eosinophilic asthma.2-7 Currently in New Zealand, benralizumab 30 mg/mL solution for injection is approved and funded for this indication subject to eligibility criteria.
Please login below to download this issue (PDF)